Direct-compression tablet matrices impose particle-size constraints on Citrus aurantium synephrine HCl

Synephrine hydrochloride derived from Citrus aurantium L. var. amara peel is supplied as a crystalline powder with a pharmacopoeial assay tolerance of 95.0%–105.0% on the dried basis. Direct-compression tablet manufacture requires the API particle size distribution to be controlled because the dose per tablet is typically 10 mg to 25 mg of synephrine base. A D90 above 250 µm increases segregation potential in low-dosage blends and drives content uniformity acceptance values above 15 per USP <905>. Batches are pre-sieved through a 150 µm mesh fitted to a vibratory screener. The blend consists of microcrystalline cellulose PH102, spray-dried lactose monohydrate, croscarmellose sodium 2.0% w/w, and magnesium stearate 0.5% w/w. Mixing occurs in a 300 L V-blender at 12 rpm for 15 min. Pre-lubrication blending is followed by lubrication for 3 min. Compression on a 16-station rotary tablet press with tooling diameter 8 mm requires a compression force of 8 kN to 14 kN. Hardness is maintained between 5 kp and 8 kp, and friability is kept below 1.0% per USP <1216>. If material loss on drying exceeds 1.0%, a pre-drying step at 40°C for 2 h in a tray dryer is applied before blending. The finished immediate-release tablets are tested for dissolution in 900 mL of 0.1 M hydrochloric acid using USP Apparatus II at 50 rpm, with a Q value of 80% dissolved in 30 min. Compliance is completed under 21 CFR 211, with residual solvent limits aligned to ICH Q3C and elemental impurities to ICH Q3D.

Across a low-dose synephrine hydrochloride capsule filling line, segregation-driven content-uniformity risk dominates batch rejection rates. The API mass per capsule is commonly 10 mg to 30 mg against a fill weight of 200 mg to 250 mg. The raw API is pre-blended with lactose monohydrate 200 mesh at a 1:10 ratio in a 50 L bin blender for 10 min. Geometric dilution is then extended to the full batch size. Colloidal silicon dioxide is added at 0.5% w/w to improve flow because synephrine HCl has a more angular crystal habit than typical direct-compression grades. A dosator-type capsule filling machine with pin diameter 6.0 mm and fill cam height adjusted to achieve relative standard deviation below 2.0% is used. The powder bed is sampled at 10-point locations after 5 min, 10 min, and 15 min of mixing to verify blend uniformity using HPLC with UV detection at 224 nm. The final blend must show an acceptance value not exceeding 15 per USP <905>. Hard gelatin capsules of size 3 are filled at a relative humidity below 40% to prevent shell deformation caused by synephrine HCl moisture uptake. Moisture uptake above 60% RH can raise the API degradation rate through hydrolysis of the phenolic amine; therefore storage containers include desiccant canisters and are sealed under nitrogen. The finished capsules comply with 21 CFR 211 and are tested for disintegration per USP <701> using water at 37°C with a maximum disintegration time of 15 min.

What limits injectable synephrine tartrate solubility during isotonic formulation?

Injectable synephrine tartrate solution is prepared at a concentration of 1.0 mg/mL to 2.0 mg/mL expressed as synephrine base in Water for Injection. The solubility limit of synephrine tartrate in water at 25°C exceeds 50 mg/mL, but the solution pH must remain between 4.0 and 5.5 to balance oxidative stability and venous tolerance. At pH below 4.0, the solution may cause injection-site pain and phlebitis; at pH above 5.5, the phenolic hydroxyl group undergoes accelerated oxidation under residual oxygen headspace. The solution must not be combined with alkaline buffers; synephrine free base precipitates above pH 6.0. The formulation is compounded in a 316L stainless-steel vessel with a nitrogen overlay. Sodium chloride is added to achieve osmolality of 270 mOsm/kg to 320 mOsm/kg. Sodium metabisulfite is included at 0.1% w/v as an oxygen scavenger when terminal sterilisation is employed. The solution is filtered through a 0.22 µm PVDF cartridge filter into depyrogenated Type I glass ampoules. Terminal sterilisation is performed at 121°C for 15 min only when the pH is held at 4.5 ±0.2; outside this range, thermal degradation of synephrine tartrate increases by approximately 0.3% per degree Celsius and cannot be accepted for commercial batch release. Finished injection is tested for visible particulates per USP <790>, subvisible particulate matter per USP <788>, and bacterial endotoxins per USP <85> with a limit of 0.5 EU/mg or lower for parenteral administration. The injectable product is used as a vasopressor in intraoperative hypotension management in jurisdictions where parenteral synephrine is registered; published comparative efficacy data for this specific synephrine tartrate concentration is limited.

In fluid-bed granulation of hydroalcoholic Citrus aurantium extracts, hygroscopicity must be controlled before sachet filling. The extract is first adsorbed onto microcrystalline cellulose at an extract-to-carrier ratio of 1:0.5 w/w to reduce sticking. Povidone K30 is dissolved in purified water to form a binder solution at 3.0% w/w relative to the dry powder charge. Granulation is performed in a top-spray fluid-bed processor equipped with a 120 L bowl. The inlet air temperature is set at 55°C to 65°C, the product temperature is maintained at 35°C to 40°C, and the spray rate is 8 g/min to 12 g/min per kg of powder. After spraying, drying continues until the loss on drying falls below 2.0%. The dried granules are passed through a 850 µm sieve and retained on a 250 µm sieve; the fraction outside this range is re-milled and re-sieved. A final blending step with sodium starch glycolate 2.0% w/w and magnesium stearate 0.5% w/w is performed in a 200 L conical screw blender for 5 min. The finished sachet contains 500 mg granules delivering the equivalent of 20 mg synephrine base per unit dose. The granule bitterness is masked by a subsequent ethylcellulose coating at 5% weight gain in a Wurster insert with inlet temperature 45°C. Dissolution testing uses USP Apparatus II in 500 mL water at 75 rpm, with not less than 75% released in 45 min. Compliance is maintained under 21 CFR 211, and the powder flow is characterised by the European Pharmacopoeia method 2.9.36 for bulk and tapped density. The finished granules are filled into aluminium-foil sachets under nitrogen to limit oxidative degradation of the flavonoid fraction.

Sustained-release matrix pharmacokinetics and polymer ratio boundaries

Hydrophilic matrix tablets containing 15 mg synephrine base per unit are manufactured by direct compression using hypromellose K100M as the rate-controlling polymer. The drug-to-polymer ratio is varied between 1:2 and 1:4 w/w. At 1:2, the gel layer formed during dissolution is insufficient to prevent dose dumping in pH 1.2; at 1:4, the release tail extends beyond 14 h and fails the extended-release acceptance criterion of ≥80% dissolved at 12 h. The optimised ratio is therefore 1:3 w/w. Lactose monohydrate is used as a soluble filler at 25% w/w, and microcrystalline cellulose at 35% w/w provides compaction. Magnesium stearate is limited to 0.75% w/w because higher concentrations slow dissolution by hydrophobic film formation. Compression is performed on a 12-station rotary press equipped with pre-compression rollers. Main compression force is held at 10 kN to 14 kN. Hardness is measured at 8 kp to 12 kp; above 14 kp, tablet porosity falls below 10% and the dissolution rate drops below the lower acceptance limit. Dissolution testing uses USP Apparatus I at 100 rpm for the first 2 h in 750 mL of 0.1 M hydrochloric acid, followed by addition of 250 mL of 0.2 M tribasic sodium phosphate to reach pH 6.8. The release specification is 20%–30% at 2 h, 50%–70% at 8 h, and ≥80% at 12 h per USP <724>. Batch-to-batch variability in synephrine HCl particle size affects gel-layer formation; incoming lots are therefore controlled to a D50 of 75–125 µm and a D90 below 200 µm. The finished product is tested for content uniformity per USP <905> and for organic impurities by HPLC with a total degradation product limit of 1.0%. Compliance is completed under 21 CFR 210 and 211.

When paediatric dosing demands taste-masked granules, particle coating becomes a processing gateway

Citrus aurantium extract contains limonin and naringin, which impart a bitterness threshold in aqueous suspension below 6 ppm. Paediatric oral granules intended for reconstitution are therefore coated with Eudragit E100, a cationic methacrylate copolymer that is insoluble in saliva pH 6.8–7.4 but dissolves rapidly in gastric fluid below pH 5.0. The coating solution is prepared by dissolving Eudragit E100 at 10% w/w in a solvent mixture of isopropyl alcohol and acetone in a 1:1 ratio. Coating is applied in a Wurster fluid-bed system with inlet air temperature 40°C to 45°C, product temperature 28°C to 32°C, and spray rate 6 g/min per kg of granules. A 5% weight gain is sufficient to suppress bitterness, but a 10% weight gain delays release in simulated gastric fluid beyond 15 min and is not used. The coated granules are dried for 30 min at 40°C and sieved through 500 µm. Residual solvent testing per ICH Q3C Class 2 limits is performed before release; isopropyl alcohol must not exceed 50 ppm and acetone must not exceed 500 ppm. The final granules are filled into unit-dose cups at a weight delivering 5 mg synephrine base per dose. Uniformity of dosage units is tested per USP <905>. The reconstituted suspension is prepared by adding 5 mL water; its pH is adjusted to 4.5 with citric acid to trigger rapid Eudragit E dissolution in the stomach. Because synephrine HCl is sensitive to oxidative degradation in aqueous suspension, the reconstituted product is used within 24 h and stored between 2°C and 8°C. The manufacturing process complies with 21 CFR 211 and the coated granules are tested for dissolution per USP <711> using 500 mL of 0.1 M hydrochloric acid at 50 rpm, with at least 80% released in 30 min.